Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Christos Chouaid (), Lionel Bensimon, Emilie Clay, Aurélie Millier, Laurie Levy-Bachelot, Min Huang and Pierre Lévy
Additional contact information
Christos Chouaid: CIC - Biotherapie - CHU Henri Mondor - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Henri Mondor - INSERM - Institut National de la Santé et de la Recherche Médicale - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12, CRETEIL - Pneumologie - Service de Pneumologie - CHI Créteil, U955 Inserm - UPEC - IMRB - CEPIA/"Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health" [Créteil] - IMRB - Institut Mondor de Recherche Biomédicale - INSERM - Institut National de la Santé et de la Recherche Médicale - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12
Lionel Bensimon: MSD - Merck Sharp & Dohme Corp. - Whitehouse Station
Emilie Clay: Evaluation des systèmes de soins et santé perçue - Université de la Méditerranée - Aix-Marseille 2, Creativ-Ceutical France - Creativ-Ceutical
Aurélie Millier: Creativ-Ceutical France - Creativ-Ceutical, Creativ-Ceutical - Creativ-Ceutical SARL
Laurie Levy-Bachelot: MSD - Merck Sharp & Dohme Corp. - Whitehouse Station
Min Huang: Merck & Co. Inc - Merck Sharp and Dohme
Pierre Lévy: LEDa - Laboratoire d'Economie de Dauphine - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres, Legos - Laboratoire d'Economie et de Gestion des Organisations de Santé - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres, LEDa - Laboratoire d'Economie de Dauphine - IRD - Institut de Recherche pour le Développement - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Keywords: Advanced NSCLC; PD-L1 positive; Cost effectiveness; Pembrolizumab; Economics (search for similar items in EconPapers)
Date: 2019
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Published in Lung Cancer, 2019, 127, ⟨10.1016/j.lungcan.2018.11.008⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-02273984

DOI: 10.1016/j.lungcan.2018.11.008

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().